Genomma Lab InternacionalB de CV (MEX:LABB) PB Ratio: 1.26 (As of Jun. 26, 2026) — 39% Below Median


MEX:LABB Genomma Lab Internacional SAB de CV MEX:LABB
66 GF Score
Price MXN15.04
GF Value MXN17.64
Valuation Modestly Undervalued
! 4 Warning Signs
View Full Analysis

What is Genomma Lab InternacionalB de CV PB Ratio?

Genomma Lab InternacionalB de CV MEX:LABB +2.59% 66 PB Ratio is 1.26 as of Jun. 26, 2026, which is 39% below its 10-year median of 2.07. GuruFocus rates MEX:LABB with a GF Score™ of 66/100 and a GF Value™ of MXN17.64 (Modestly Undervalued). The stock has 4 warning signs investors should review. Among 922 Drug Manufacturers companies, Genomma Lab InternacionalB de CV ranks better than 66.81% on this metric.

The PB Ratio, or Price-to-Book ratio, or Price/Book, is a financial ratio used to compare a company's market price to its Book Value per Share. As of today (2026-06-26), Genomma Lab InternacionalB de CV's share price is MXN15.04. Genomma Lab InternacionalB de CV's Book Value per Share for the quarter that ended in Mar. 2026 was MXN11.98. Hence, Genomma Lab InternacionalB de CV's PB Ratio of today is 1.26.

Good Sign:

Genomma Lab Internacional SAB de CV stock PB Ratio (=1.25) is close to 10-year low of 1.16.

The historical rank and industry rank for Genomma Lab InternacionalB de CV's PB Ratio or its related term are showing as below:

MEX:LABB' s PB Ratio Range Over the Past 10 Years
Min: 1.16   Med: 2.07   Max: 4.1
Current: 1.25

During the past 13 years, Genomma Lab InternacionalB de CV's highest PB Ratio was 4.10. The lowest was 1.16. And the median was 2.07.

MEX:LABB's PB Ratio is ranked better than
66.81% of 922 companies
in the Drug Manufacturers industry
Industry Median: 1.825 vs MEX:LABB: 1.25

During the past 12 months, Genomma Lab InternacionalB de CV's average Book Value Per Share Growth Rate was 5.00% per year. During the past 3 years, the average Book Value Per Share Growth Rate was 2.60% per year. During the past 5 years, the average Book Value Per Share Growth Rate was 4.70% per year. During the past 10 years, the average Book Value Per Share Growth Rate was 5.80% per year.

During the past 13 years, the highest 3-Year average Book Value Per Share Growth Rate of Genomma Lab InternacionalB de CV was 107.20% per year. The lowest was -12.70% per year. And the median was 10.00% per year.

Back to Basics: PB Ratio


Genomma Lab InternacionalB de CV  (MEX:LABB) PB Ratio Explanation

Unlike valuation ratios relative to the earning power such as PE Ratio, PE Ratio without NRI, PS Ratio, Price-to-Operating-Cash-Flow , or Price-to-Free-Cash-Flow, the PB Ratio measures the valuation of the stock relative to the underlying asset of the company.

The PB Ratio works the best for the businesses that earn most of their profit from their assets, e.g. banks and insurance companies.


Be Aware

Some businesses have very light assets, such as software companies or insurance agencies. The PB Ratio does not work well for these companies. Some companies even have negative equity, so the PB Ratio cannot be applied to them.


Genomma Lab InternacionalB de CV PB Ratio Related Terms


Genomma Lab InternacionalB de CV PB Ratio Historical Data

* Premium members only.

The historical data trend for Genomma Lab InternacionalB de CV's PB Ratio can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Genomma Lab InternacionalB de CV PB Ratio Chart

Genomma Lab InternacionalB de CV Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
PB Ratio
Get a 7-Day Free Trial Premium Member Only Premium Member Only 2.14 1.60 1.43 2.28 1.58

Genomma Lab InternacionalB de CV Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
PB Ratio Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 2.22 1.77 1.71 1.58 1.52

MEX:LABB vs ZTS, UTHR, VTRS: PB Ratio Comparison

For the Drug Manufacturers - Specialty & Generic subindustry, Genomma Lab InternacionalB de CV's PB Ratio, along with its competitors' market caps and PB Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Genomma Lab InternacionalB de CV PB Ratio vs Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Genomma Lab InternacionalB de CV's PB Ratio distribution charts can be found below:

* The bar in red indicates where Genomma Lab InternacionalB de CV's PB Ratio falls into.


MEX:LABB
66GF Score
Genomma Lab Internacional SAB de CV MEX:LABB
PB Ratio is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Genomma Lab InternacionalB de CV PB Ratio Calculation

The PB Ratio, or Price-to-Book ratio, or Price/Book, is a financial ratio used to compare a company's market price to its Book Value per Share. It is a ratio widely used to value stocks.

Genomma Lab InternacionalB de CV's PB Ratio for today is calculated as follows:

PB Ratio=Share Price/Book Value per Share (Q: Mar. 2026)
=15.04/11.982
=1.26

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

It can also be calculated from the numbers for the whole company:

A closely related ratio is called Price-to-Tangible-Book. The difference between Price-to-Tangible-Book and PB Ratio is that book value other than intangibles are used in the calculation.

Frequently Asked Questions Learn more about PB Ratio →
What does a PB Ratio of 1.26 mean?
Genomma Lab InternacionalB de CV (MEX:LABB) has a PB Ratio of 1.26 as of Jun. 26, 2026. Price-to-Book ratio is the ratio of share price to a company's book value per share. View historical data on Genomma Lab InternacionalB de CV and its competitors. This is 39% below median its historical median of 2.07. Over the past decade, Genomma Lab InternacionalB de CV's PB Ratio has ranged from 1.16 to 4.10. According to the industry distribution chart, Genomma Lab InternacionalB de CV ranks #306 out of 922 companies in the Drug Manufacturers industry, placing it in the top 33.2%.
Is Genomma Lab InternacionalB de CV's PB Ratio too high?
Genomma Lab InternacionalB de CV's current PB Ratio of 1.26 is 39% below median its 10-year median of 2.07. Over the past 10 years, this metric has ranged from a low of 1.16 to a high of 4.10. The Drug Manufacturers industry median PB Ratio is 1.83. Genomma Lab InternacionalB de CV's value of 1.26 is 31% below this industry median. Based on the distribution chart, Genomma Lab InternacionalB de CV ranks #306 out of 922 companies in the Drug Manufacturers industry, which is above the industry midpoint. Overall, Genomma Lab InternacionalB de CV has a GF Score™ of 66/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Genomma Lab InternacionalB de CV's PB Ratio compare to ZTS and UTHR?
According to the Drug Manufacturers industry distribution chart, Genomma Lab InternacionalB de CV ranks #306 out of 922 companies for PB Ratio. This puts Genomma Lab InternacionalB de CV in the upper half of its industry. The industry median PB Ratio is 1.83. Genomma Lab InternacionalB de CV's value of 1.26 is 31% below this benchmark. Historically, Genomma Lab InternacionalB de CV's own PB Ratio has ranged from 1.16 to 4.10 over the past decade. While the company's 10-year median is 2.07 vs. the industry median of 1.83, Genomma Lab InternacionalB de CV has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good PB Ratio for a Drug Manufacturers company?
The median PB Ratio among Drug Manufacturers companies is 1.83, based on 922 companies in the industry. Companies in the top quartile (top 25%) have a PB Ratio significantly above this median, while those in the bottom quartile fall well below. However, PB Ratio should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Genomma Lab InternacionalB de CV's current PB Ratio of 1.26 is 31% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high PB Ratio mean?
A high PB Ratio can signal that a stock is expensive relative to its fundamentals. Price-to-Book ratio is the ratio of share price to a company's book value per share. View historical data on Genomma Lab InternacionalB de CV and its competitors. For the Drug Manufacturers industry, the median PB Ratio is 1.83 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Genomma Lab InternacionalB de CV's current PB Ratio is 1.26, which is 39% below median its own 10-year median of 2.07. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Genomma Lab InternacionalB de CV stock overvalued right now?
Based on GuruFocus' analysis, Genomma Lab InternacionalB de CV (MEX:LABB) is currently considered Modestly Undervalued. The stock's GF Value™ is MXN17.64, compared to a current price of MXN15.04 — trading 14.7% below its estimated fair value. The current PB Ratio is 1.26, which is 39% below median its 10-year median of 2.07 and 31% below the Drug Manufacturers industry median of 1.83. Genomma Lab InternacionalB de CV's overall GF Score™ is 66/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is PB Ratio calculated?
PB Ratio is calculated from a company's financial statements. For Genomma Lab InternacionalB de CV (MEX:LABB), the current PB Ratio is 1.26 as of Jun. 26, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Genomma Lab InternacionalB de CV (MEX:LABB) Overvalued in 2026?

Based on GuruFocus' analysis, Genomma Lab InternacionalB de CV stock appears to be undervalued. The current stock price of MXN15.04 is trading 14.7% below its estimated GF Value™ of MXN17.64. GuruFocus considers Genomma Lab InternacionalB de CV to be Modestly Undervalued.

Key valuation signals for MEX:LABB:

  • PB Ratio: 1.26 (39% below median its 10-year median of 2.07)
  • GF Value™: MXN17.64 vs. price of MXN15.04 (14.7% below fair value)
  • GF Score™: 66/100 with 4 warning signs
  • Industry Position: 31% below the Drug Manufacturers median (#306 of 922)

No single metric tells the full story. See the MEX:LABB stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


Genomma Lab InternacionalB de CV Business Description

Other Exchanges GNMLF:USAGEKA:Germany
Address Avenida Antonio Dovali Jaime, Number 70, Tower C, Floor 2, Office A. Colonia Santa Fe, Del. Alvaro Obregon, Mexico, MEX, MEX, CP 01210
Genomma Lab Internacional SAB de CV is a specialty and generic drug manufacturer. The company's stated goal is to improve and preserve the health and well-being of people through innovative, safe, and effective products. Genomma operates a wide variety of brands to serve different consumer needs, including pregnancy, pain medication, and deodorant. The company considers merger and acquisition investment as a potential component of its operational growth strategy for expanding its research, development, manufacturing, and marketing capabilities.
66GF Score

Get the complete analysis for MEX:LABB

PB Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

MXN15.04
Price
MXN17.64
GF Value